Endovascular Simulation Specialist Mentice Appoints Chief Clinical Officer
Mentice, the world leading provider of endovascular performance solutions, today announced the appointment of Dr. David J. Ballard as Chief Clinical Officer and Executive Vice President of the Mentice Group. Dr. Ballard was previously appointed an independent member of the Mentice board of directors in October 2018.
“I am excited to join the Mentice executive team, in addition to continuing to engage my existing role on the Mentice board,” says Dr. Ballard. “I have spent the last couple of months educating myself on the opportunities to leverage Mentice solutions to reduce harm to patients, and to make health care more affordable. We have excellent opportunities to make significant contributions towards achieving both these objectives in partnership with healthcare systems across the world.”
Dr. Ballard (M.D., M.S.P.H., Ph.D., F.A.C.P.) is a health care executive with proven expertise in improving healthcare value and organizational financial performance, while providing international thought leadership. Dr. Ballard was recognized by Becker’s Hospital Review as one of the top 50 experts leading the field of patient safety in 2015, 2016, 2017 and 2018.
A past president of the International Society for Quality in Health Care, Dr. Ballard in 2008 received the Distinguished Alumnus Award from the University of North Carolina School of Medicine. Widely recognized as a scholar in health care quality and value, his two books on health care quality leadership have received Shingo Awards for their contributions to operational excellence.
Dr. Ballard served the past 19 years as Chief Quality Officer of Baylor Scott & White Health, the largest health care system in Texas. He has also served in leadership roles at Emory University (1994-1999), University of Virginia (1991-1994) and the Mayo Clinic. He holds degrees in economics, epidemiology and medicine from the University of North Carolina where he was a John Motley Morehead Scholar. Dr. Ballard trained in internal medicine at the Mayo Clinic and served from 1986-91 on the Mayo staff as Consultant, Associate Professor and Head of the Section of Health Services Evaluation, where he now serves as Healthcare Policy Section Editor for the Mayo Clinic Proceedings. Dr. Ballard is a member of the Chancellor’s Global Leadership Council at the University of North Carolina where he is also Adjunct Professor of Health Policy and Management in the UNC Gillings School of Global Public Health.
“I’m thrilled to welcome Dr. Ballard to our team,” says Goran Malmberg, Group CEO of Mentice. “Dr. Ballard will help drive our engagement with health systems, and I cannot think of a better person for this role. Mentice has a unique technology and a market-leading position with premier medical device corporations and academic institutes worldwide. We believe the largest opportunity for our solutions is within the field of continuous practice and with leading health systems—areas where we are just beginning.”
Mentice is the world leader in virtual reality‐based interventional medical simulation solutions. Our solutions help healthcare professionals with skills acquisition, continuous development and pre-procedural planning—leading to improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical industry. Neurovascular, cardiovascular and peripheral interventions are just some of the areas covered by our systems. For more information about Mentice, visit www.mentice.com.
For more information:
Stacy Hammar, Marketing Coordinator
+46 (0) 31 339 94 94
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Rimini Street CEO Visits Seoul, Addresses Changing IT Mission19.3.2019 23:00:00 CET | Pressemelding
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, is committed to helping South Korean companies reduce ongoing IT operating costs and freeing up significant IT budget to invest in innovation, competitive advantage and growth, co-founder and CEO Seth A. Ravin explained during a press conference in Seoul. Mr. Ravin also highlighted continued strong and growing demand in Korea for the Company’s award-winning, ultra-responsive enterprise software support model, which is disrupting the $160 billion enterprise software maintenance market worldwide. As the 4th largest economy in Asia, and the 11th largest in the world, South Korea represents a large market opportunity for the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005832/en/ Rimini Street CEO Visits Seoul,
SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer19.3.2019 20:00:00 CET | Pressemelding
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50 th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented during today’s SGO 2019 Plenary Session by SOV02 principal investigator David Cibula, MD, PhD from General University Hospital in Prague (Czech Republic). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005837/en/ In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy. Compared to patients who did not receive DCVAC, it decreased the risk of death by 62%. The combinati
OCP Announces Date of Fourth Quarter and Full Year 2018 Earnings19.3.2019 19:00:00 CET | Pressemelding
OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2018 results on Monday, March 25, 2019. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco time (GMT+1), and 1:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss fourth quarter and full year 2018 results at 10:00 a.m. EDT, 3:00 p.m. Morocco time (GMT+1), and 2:00 p.m. London time (GMT) on Monday, March 25, 2019 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing firstname.lastname@example.org About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s
HCL and Xerox Expand Strategic Partnership to Accelerate Operational Transformation19.3.2019 16:51:00 CET | Pressemelding
HCL Technologies (HCL), a leading global technology company, announced that it signed a managed services agreement with Xerox (NYSE: XRX). Under the terms of the agreement, HCL will manage portions of Xerox’s shared services, including global administrative and support functions, including, among others, selected information technology and finance functions (excluding accounting). Leveraging HCL’s global scale and capabilities, Xerox will strategically evolve its shared services into process-first, technology-led digital operations. This seven-year agreement for an incremental $1.3 billion continues to build on the success of the Xerox-HCL relationship, which began in 2009 with product engineering and support services. Under that agreement, HCL currently manages aspects of Xerox’s mechanical, electrical and software engineering activities for printer and imaging product lines. Together, HCL and Xerox have delivered 215 U.S. patents and have created world-class R&D labs that are tightly
Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases19.3.2019 15:18:00 CET | Pressemelding
Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis. The 18-month program includes: development of a research cell bank using Abzena’s proprietary cell line and ambr® 15 automated high throughput bioreactors, generation of master cell banks, scale up using an ambr® 250 during process development, followed by cGMP manufacturing in Sartorius 500 L single use stirred tank bioreactors for clinical material. The work will take place at Abzena’s sites in Cambridge, UK and San Diego, USA. Jonathan Goldman, CEO of Abzena, said: “Autoimmune inflammatory diseases such as juvenile idiopathic arthritis represent significant unmet medical need. We are